Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline.

The beginning of this year is already offering a couple of data points that pick up last year’s momentum and hint at where genomics might be moving next. On January 13, during JPM week, Illumina announced the Billion Cell Atlas — a genome-wide perturbation dataset built from 1B cells meant as the foundation for large-scale target validation and AI model training. With AstraZeneca, Eli Lilly, and MSD involved, the initiative was framed as an attempt to create a standardized map of gene function that could be reused across different drug discovery programs.

Just a day earlier, MIT Technology Review published its annual 10 Breakthrough Technologies list. This year, three of the highlighted technologies were in genomics: personalized gene editing, embryo scoring, and gene resurrection. From there, it seems like genomic applications are moving more into the mainstream technology discourse.

Another just-in data point from a few days ago is a report out of San Diego, where Element Biosciences says its newly announced VITARI benchtop sequencer can deliver a whole genome for $100, positioning it as a lower-cost alternative to Illumina’s high-throughput systems.

Photo: Roche’s SBX setup

Looking at these and many of last year’s developments, genomics come into view as an integrated technology wave that extends from data generation to interpretation, intervention, and biological reconstruction.

With those early-2026 pings as a starting point, let’s do a selective pass through a few genomics patterns that seem to be carrying momentum into 2026.

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

Upgrade to Pro

Already a member? Sign in here.